Intuitive Surgical 8-K

PositiveEarningsNew guidance

da Vinci 5 placements surged alongside procedure-driven revenue growth; 2026 procedure guidance points to a slower pace.

Filed 2026-01-14 08:58 ET

Summary

Preliminary Q4 and FY2025 results, with 2026 procedure guidance. Revenue grew 19% in Q4 and 21% for the year, driven by higher procedure volume, da Vinci system placements and the larger installed base. Results remain unaudited and subject to closing and audit adjustments.

Key Figures

Metric Q4 2025 Q4 2024 Y/Y
Revenue $2.87B $2.41B 19%
Instruments and accessories revenue $1.66B $1.41B 17%
Systems revenue $786M $655M 20%
Service revenue $422M $347M 21%
da Vinci procedures (thousands) 849 725 17%
da Vinci system placements 532 493 8%
Ion system placements 42 69 (39)%
Metric FY2025 FY2024 Y/Y
Revenue $10.1B $8.35B 21%
Instruments and accessories revenue $6.02B $5.08B 19%
Systems revenue $2.47B $1.97B 26%
Service revenue $1.57B $1.31B 20%
da Vinci procedures (thousands) 3,153 2,683 18%
da Vinci system placements 1,721 1,526 13%
Ion system placements 195 271 (28)%
  • Combined da Vinci and Ion procedures grew approximately 18% in Q4 and 19% in FY2025. FY da Vinci procedure growth was 18% in the U.S. and 23% outside the U.S.
  • da Vinci 5 placements were 303 in Q4 vs 174 a year earlier, and 870 for FY2025 vs 362 in FY2024. Q4 expenses included a $70M Intuitive Foundation contribution vs $45M a year earlier.

Guidance

  • Worldwide da Vinci procedures: 2026 growth of approximately 13%–15% vs 2025.

Investor Takeaways

  • The company is scheduled to report Q4 results and discuss FY2025 results on 1/22/2026; final results may differ from these preliminary figures.
  • Track 2026 worldwide da Vinci procedure growth against the 13%–15% outlook.

The summary is written by an AI model reading the filing.

Model 005 · prompt 01d34d48e3

Feedback